Results 111 to 120 of about 17,985,271 (268)

Corticosterone and Mitochondrial Efficiency Are Associated With Changes in DNA Oxidative Damage During an Acute Stress Response in Leach's Storm‐Petrels (Hydrobates leucorhous)

Journal of Experimental Zoology Part A: Ecological and Integrative Physiology, EarlyView.
ABSTRACT The ability of organisms to effectively respond to challenges is critical for survival. We investigated how an acute stressor affected corticosterone, mitochondrial function, and DNA oxidative damage in a wild population of Leach's storm‐petrels (Hydrobates leucorhous).
Kayla E. Lichtner, Jack K. Dziubek, Nicole A. Joseph, Sarah E. Chapman, Tori J. Chace, Dongxiao Sun, Zachary T. Bitzer, Antoine Stier, Robert A. Mauck, Patricia L. Jones, Mark F. Haussmann   +10 more
wiley   +1 more source

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer's disease and related dementias? [PDF]

Brain Commun, 2022
Newby D.
europepmc   +1 more source

Association Between MRI‐Derived Right‐to‐Left Ventricular Volume Ratio and Regional Left Ventricular Myocardial Dysfunction in Patients With Pulmonary Arterial Hypertension

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Right ventricular (RV) to left ventricular (LV) end‐diastolic volume ratio (RV/LV) is a validated marker of RV dilation in pulmonary arterial hypertension (PAH), yet its impact on LV myocardial function and the underlying mediating pathway is incompletely characterized.
Han Fang, Yuan Li, Jin Wang, Wei‐Feng Yan, Ke Shi, Shi‐Qin Yu, Xue Li, Wen‐Rong Li, Jia‐Ke Li, Jing‐Yi Guo, Li Jiang, Zhi‐Gang Yang   +11 more
wiley   +1 more source

Phosphodiesterase 5 inhibitors: current status and potential applications

, 2002
Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men,
Rotella, David, David P. Rotella
core   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

Combination vardenifil and tadalifil drug induced liver injury; case report and review of the literature of liver injury associated with phosphodiesterase type 5 inhibitors. [PDF]

Can Liver J, 2023
Xu B, Braxton DR, Fong TL.
europepmc   +1 more source

Protective Effects of Riociguat Against Contrast‐Induced Nephropathy: An Experimental and Machine Learning‐Based Study in Rats

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Contrast‐induced nephropathy (CIN) is an important cause of acute kidney injury following exposure to iodinated contrast media, and effective preventive strategies remain limited. This study investigated the renoprotective effects of riociguat, a soluble guanylate cyclase stimulator, in an experimental rat model of CIN and explored machine ...
Mustafa Begenc Tascanov, Kenan Toprak, Sibel Turedi, İsmail Koyuncu, Zulkif Tanrıverdi, Necip Fazıl Dedeoglu, Halil Fedai, Asuman Bicer, İbrahim Halil Altıparmak, Recep Demirbag, Gencay Sarıısık   +10 more
wiley   +1 more source

Do phosphodiesterase type 5 inhibitors increase the risk of biochemical recurrence after radical prostatectomy?

European Urology Open Science, 2023
J.P. Mulhall, J.M.F. Flores, A.V Vickers, P.T.S Scardino   +3 more
doaj   +1 more source

Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis. [PDF]

Sex Med, 2023
Shin YE, Rojanasarot S, Hincapie AL, Guo JJ.   +3 more
europepmc   +1 more source

Non-Arteritic Anterior Ischemic Optic Neuropathy Associated With the Use of Phosphodiesterase Type 5 Inhibitors: A Literature Review. [PDF]

Cureus, 2022
Hor M, Baradeiya AM, Qasim H, Nasr M, Mohammad A.   +4 more
europepmc   +1 more source